Treatment optimization and combining metrics
NEDA – new approach
NeuroSens Survey: How do you assess treatment response in practice?

The proliferation of disease-modifying therapies (DMT) in multiple sclerosis has focused attention on the need for improved measures for evaluating treatment efficacy and response. In part, this is driven by the increasing difficulty of detecting a treatment effect in clinical trials of early MS patients with minimal disease activity, as well as the need to differentiate DMTs with respect to their varying effects on clinical and radiological endpoints. In clinical practice, identifying suboptimal responders is a matter of some urgency since therapies are more likely to provide benefit in the first 2-5 years after diagnosis of CIS/MS. An early treatment effect may be the only effect, so it is important to optimize the drug regimen before the window of opportunity for effective intervention is shuttered. Read More

Worldwide pharmaceutical sales are projected to exceed USD$1 trillion in 2020, according to an analysis by EvaluatePharma, a market intelligence company. Global sales in 2013 were $717 billion. Growth over the next seven years is projected to be about 5% per year despite a loss (-1.6%) in 2012 and minimal growth (+0.3%) in 2013. Higher growth is largely attributed to the development of biological agents, which are priced higher than pharmaceuticals and are less likely to be genericized. Read More